KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBT: 2011-2025

Historic EBT for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $25.7 million.

  • Travere Therapeutics' EBT rose 146.89% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.5 million, marking a year-over-year increase of 74.61%. This contributed to the annual value of -$320.5 million for FY2024, which is 14.78% up from last year.
  • Latest data reveals that Travere Therapeutics reported EBT of $25.7 million as of Q3 2025, which was up 301.92% from -$12.7 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year EBT high stood at $25.7 million for Q3 2025, and its period low was -$135.8 million during Q1 2024.
  • In the last 3 years, Travere Therapeutics' EBT had a median value of -$69.6 million in 2024 and averaged -$65.9 million.
  • In the last 5 years, Travere Therapeutics' EBT plummeted by 194.77% in 2021 and then surged by 146.89% in 2025.
  • Quarterly analysis of 5 years shows Travere Therapeutics' EBT stood at -$88.8 million in 2021, then grew by 3.60% to -$85.6 million in 2022, then dropped by 3.45% to -$88.5 million in 2023, then spiked by 31.84% to -$60.3 million in 2024, then surged by 146.89% to $25.7 million in 2025.
  • Its EBT was $25.7 million in Q3 2025, compared to -$12.7 million in Q2 2025 and -$41.2 million in Q1 2025.